降粘抗栓片联合依达拉奉治疗脑梗死临床观察

目的分析降粘抗栓片联合依达拉奉治疗脑梗死疗效及其对血液流变学与超氧化物歧化酶(SOD)活性的影响,并对药物抗血小板凝聚机制进行初步探讨。方法选取郑州大学附属郑州中心医院2013-02-2016-09收治的72例脑梗死患者,采用随机数字表法分为观察组(n=36)和对照组(n=36),2组均给予依达拉奉治疗,观察组加用降粘抗栓片治疗,治疗2周后统计2组总有效率,并对比2组治疗前和治疗2周后血液流变学指标红细胞沉降率(ESR)、红细胞比积(PCV)、全血还原黏度(RV)、血小板黏附率(PADT)]、SOD、血浆血栓素B_2(TXB_2)、6-酮-前列腺素F_(1α)(6-keto-PCF_(1α))水平。结果 (1)疗效:观察组总有效率为91.67%,高于对照组的69.44%,差异具有统计学意义(χ2=5.675,P0.05);(2)血液流变学指标:观察组治疗2周后PCV、RV、PADT与对照组相比明显较低,差异具有统计学意义(P0.05);(3)SOD活性:治疗2周后2组SOD均高于治疗前,且观察组高于对照组,差异具有统计学意义(P0.05);(4)抗血小板凝聚机制:治疗2周后2组TXB2均低于治疗前,6-ketoPCF_(1α)均高于治疗前,且观察组TXB2低于对照组,6-keto-PCF_(1α)高于对照组,差异具有统计学意义(P0.05)。结论降粘抗栓片联合依达拉奉治疗脑梗死可改善患者血液流变学,提高超氧化物歧化酶活性,疗效显著。

Effects of Jiangnian Kangshuan tablet combined with edaravone in the treatment of cerebral infarction patients

Objective To investigate the effects of Jiangnian Kangshuan tablet combined with edaravone on the treatment of cerebral infarction and on hemorheology and superoxide dismutase (SOD) activity,and to explore the mechanism of antiplatelet aggregation.Methods 72 patients with cerebral infarction in Zhengzhou Central Hospital Affiliated to Zhengzhou University from February 2013 to September 2016 were randomly divided into observation group (n=36) and control group (n =36).Both groups were given edaravone treatment,and the observation group additionally received Jiangnian Kangshuan tablet treatment.The total effective rate of the two groups was compared after two weeks,and the hemorheological indexes including erythrocyte sedimentation rate (ESR),packed-cell volume (PCV),whole blood reduced viscosity (RV),platelet adhesion rate (PADT),SOD,plasma TXB2 and 6-keto-PCF1α were measured.Results (1) Curative effect:The total effective rate was 91.67 ％ in the observation group and 69.44％ in the control group,and the difference was statistically significant (x2 5.675,P＜0.05);(2) Hemorheological indexes:Compared with the control group,the PCV,RX and PADT in the observation group were significantly lower than those in the control group at 2 weeks after treatment (P＜0.05);(3) SOD activity:Two weeks After treatment,the SOD level of the two groups was higher than that before treatment,and the observation group showed higher SOD level than the control group (P ＜0.05);(4) Anti-platelet aggregation mechanism:TXB2 level was decreased and 6-keto-PCF1α level was increased in both two groups after treatment,and compared with control group,the observation group showed lower TXB2 level and higher 6-keto-PCF1α level (all P＜0.05).Conclusion The treatment of Jiangnian Kangshuan tablet combined with edaravone can improve the hemorheology and the activity of superoxide dismutase with beneficial clinical efficacy.